MDT

96.83

-2.02%↓

A

139.62

-3.71%↓

VEEV

222.3

+1.47%↑

HQY

85.02

-2.1%↓

NEOG

9.24

-2.22%↓

MDT

96.83

-2.02%↓

A

139.62

-3.71%↓

VEEV

222.3

+1.47%↑

HQY

85.02

-2.1%↓

NEOG

9.24

-2.22%↓

MDT

96.83

-2.02%↓

A

139.62

-3.71%↓

VEEV

222.3

+1.47%↑

HQY

85.02

-2.1%↓

NEOG

9.24

-2.22%↓

MDT

96.83

-2.02%↓

A

139.62

-3.71%↓

VEEV

222.3

+1.47%↑

HQY

85.02

-2.1%↓

NEOG

9.24

-2.22%↓

MDT

96.83

-2.02%↓

A

139.62

-3.71%↓

VEEV

222.3

+1.47%↑

HQY

85.02

-2.1%↓

NEOG

9.24

-2.22%↓

Search

Cytek Biosciences Inc

Затворен

СекторЗдравеопазване

5.39 -3.92

Преглед

Промяна на цената на акция

24 ч

Текуща

Минимум

5.38

Максимум

5.48

Ключови измерители

By Trading Economics

Приходи

105K

-5.5M

Продажби

6.7M

52M

EPS

-0

Марж на печалбата

-10.476

Служители

692

EBITDA

6.4M

-4.2M

Препоръки

By TipRanks

Препоръки

Купи

12-месечна прогноза

+10.97% upside

Дивиденти

By Dow Jones

Следващи печалби

26.02.2026 г.

Пазарни показатели

By TradingEconomics

Пазарна капитализация

240M

742M

Предишно отваряне

9.31

Предишно затваряне

5.39

Настроения в новините

By Acuity

17%

83%

18 / 361 Класиране в Healthcare

Техническа оценка

By Trading Central

Увереност

Weak Bullish Evidence

Cytek Biosciences Inc Графика

Миналото представяне не гарантира бъдещи резултати.

Свързани новини

16.01.2026 г., 23:29 ч. UTC

Горещи акции

Stocks to Watch: Atossa Therapeutics, Union Pacific

16.01.2026 г., 22:48 ч. UTC

Придобивния, сливания и поглъщания

Rail Regulator Sends $71.5 Billion Union Pacific-Norfolk Southern Deal Back for Redo -- 2nd Update

16.01.2026 г., 22:43 ч. UTC

Придобивния, сливания и поглъщания

Union Pacific: Additional Information Requested to Be Provided to Surface Transportation Board

16.01.2026 г., 22:22 ч. UTC

Придобивния, сливания и поглъщания

Rail Regulator Sends $71.5 Billion Union Pacific-Norfolk Southern Deal Back for Redo -- Update

16.01.2026 г., 21:50 ч. UTC

Пазарно говорене
Придобивния, сливания и поглъщания

Tech, Media & Telecom Roundup: Market Talk

16.01.2026 г., 21:50 ч. UTC

Пазарно говорене
Придобивния, сливания и поглъщания

Auto & Transport Roundup: Market Talk

16.01.2026 г., 21:50 ч. UTC

Пазарно говорене

Basic Materials Roundup: Market Talk

16.01.2026 г., 21:50 ч. UTC

Пазарно говорене

Health Care Roundup: Market Talk

16.01.2026 г., 21:48 ч. UTC

Пазарно говорене
Придобивния, сливания и поглъщания

Union Pacific, Norfolk Southern Market Share Ruled as Faulty -- Market Talk

16.01.2026 г., 21:41 ч. UTC

Пазарно говорене
Придобивния, сливания и поглъщания

Union Pacific, Norfolk Southern Deal Rejection Leaves Questions -- Market Talk

16.01.2026 г., 21:38 ч. UTC

Придобивния, сливания и поглъщания

Rail Regulator Sends $71.5 Billion Union Pacific-Norfolk Southern Deal Back for Redo -- WSJ

16.01.2026 г., 21:30 ч. UTC

Придобивния, сливания и поглъщания

STB: Union Pacific, Norfolk Southern Application Doesn't Include 'Projected Market Shares' as Required

16.01.2026 г., 21:30 ч. UTC

Придобивния, сливания и поглъщания

STB: Union Pacific, Norfolk Southern Application Doesn't Include Certain Schedules, Documents Expressly Made Part of Merger Agreement

16.01.2026 г., 21:30 ч. UTC

Придобивния, сливания и поглъщания

STB: Union Pacific, Norfolk Southern Application Doesn't Contain Certain Information Required by Regulations

16.01.2026 г., 21:30 ч. UTC

Придобивния, сливания и поглъщания

STB: Application Rejected Without Prejudice to Union Pacific, Norfolk Southern Refiling Revised Application Remedying Deficiencies

16.01.2026 г., 21:30 ч. UTC

Придобивния, сливания и поглъщания

Surface Transportation Board: Union Pacific, Norfolk Southern Major Merger Application Filed Dec. 19 Incomplete

16.01.2026 г., 20:44 ч. UTC

Печалби

5 Takeaways From This Season's Wealth Management Earnings -- Barrons.com

16.01.2026 г., 20:42 ч. UTC

Пазарно говорене

Oil Futures Post Fourth Straight Weekly Gain -- Market Talk

16.01.2026 г., 20:28 ч. UTC

Пазарно говорене

U.S. Natural Gas Slips Ahead of Long Weekend -- Market Talk

16.01.2026 г., 19:12 ч. UTC

Пазарно говорене
Придобивния, сливания и поглъщания

Netflix Could Comment on Structure of Warner Bid During 4Q Results -- Market Talk

16.01.2026 г., 18:53 ч. UTC

Пазарно говорене

Global Crude Supply Enough to Absorb Any Iran Disruption -- Market Talk

16.01.2026 г., 18:41 ч. UTC

Пазарно говорене

Netflix's Ad Business Seen as Primary Revenue Driver in 2026 -- Market Talk

16.01.2026 г., 18:31 ч. UTC

Пазарно говорене

U.S. Oil Rig Count Rises By 1 to 410 -- Market Talk

16.01.2026 г., 17:20 ч. UTC

Пазарно говорене

Financial Services Roundup: Market Talk

16.01.2026 г., 17:20 ч. UTC

Пазарно говорене

Basic Materials Roundup: Market Talk

16.01.2026 г., 17:20 ч. UTC

Пазарно говорене

Health Care Roundup: Market Talk

16.01.2026 г., 17:03 ч. UTC

Пазарно говорене

Global Equities Roundup: Market Talk

16.01.2026 г., 17:03 ч. UTC

Пазарно говорене

All Eyes on Guidance for European Big Pharma Earnings Season -- Market Talk

16.01.2026 г., 16:32 ч. UTC

Пазарно говорене
Придобивния, сливания и поглъщания

Sanofi Needs Dealmaking to Offset Pipeline Disappointments -- Market Talk

16.01.2026 г., 16:20 ч. UTC

Пазарно говорене

Global Equities Roundup: Market Talk

Сравнение с други в отрасъла

Ценова промяна

Cytek Biosciences Inc Прогноза

Ценова цел

By TipRanks

10.97% нагоре

12-месечна прогноза

Среден 6.17 USD  10.97%

Висок 7.5 USD

Нисък 5 USD

Според 3 анализатори от Wall Street, предложили 12-месечна ценова цел за Cytek Biosciences Inc през последните три месеца.

Консенсусна оценка

By TipRanks

Купи

3 ratings

2

Купи

1

Задържане

0

Продай

Техническа оценка

By Trading Central

3.7 / 3.8Подкрепа & съпротива

Краткосрочен план

Weak Bullish Evidence

Средносрочен план

Bearish Evidence

Дългосрочен план

Bearish Evidence

Настроение

By Acuity

18 / 361 Класиране в Здравеопазване

Настроения в новините

Много силни бичи доказателства

Волатилност

Под средното

Обем новини (RCV)

Среден

Финанси

Продажбени и админисративни разходи

Оперативни разходи

Печалба преди облагане с данъци

Продажби

Разходи за продажби

Брутна печалба от продажби

Разходи за лихви по дълг

EBITDA

Оперативна печалба

$

Относно Cytek Biosciences Inc

Cytek Biosciences, Inc., a cell analysis solutions company, provides cell analysis tools that facilitates scientific advances in biomedical research and clinical applications. It offers aurora and northern lights systems, which are spectrum flow cytometers that delivers cell analysis by utilizing the fluorescence signatures from multiple lasers to distinguish fluorescent tags on single cells; and aurora cell sorter system that leverages full spectrum profiling technology to further broaden potential applications across cell analysis; aurora CS systems; amnis imagestream imaging flow cytometers; guava muse cell analyzers; guava easycyte flow cytometers; and orion reagent cocktail preparation systems. The company also provides reagents and kits, including cFluor reagents that are fluorochrome conjugated antibodies used to identify cells of interest for analysis on its instruments, as well as 25-color immunoprofiling assay that provides turnkey solutions for identifying major human immune subpopulations for TBNK cells, monocytes, dendritic cells, and basophils. In addition, it offers automated micro-sampling system and automated sample loader system, an automated loaders to integrate seamlessly into the aurora and northern lights systems; SpectroFlo software that provides intuitive workflow from quality control to data analysis for aurora and northern lights systems; and customer support tools. The company serves pharmaceutical and biopharma companies, academic research centers, and clinical research organizations. It distributes its products through direct sales force and support organizations in North America, Europe, China, and the Asia-Pacific regions; and through distributors or sales agents in European, Latin American, and the Middle Eastern countries. The company was formerly known as Cytoville, Inc. and changed its name to Cytek Biosciences, Inc. in August 2015. Cytek Biosciences, Inc. was founded in 1992 and is headquartered in Fremont, California.
help-icon Live chat